Prolactin in Human Reproduction

Molitch, Mark E.

doi:10.1016/b978-1-4557-2758-2.00003-2

Cited by 6 publications

(2 citation statements)

References 455 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A diferencia de lo reportado en la literatura, en nuestras pacientes fue infrecuente el consumo de medicamentos relacionados con elevación del nivel de prolactina; los más frecuentes fueron los antidepresivos tricícli-cos y los inhibidores de la recaptación de serotonina. Otros autores han hallado que los fármacos son la causa más común de hiperprolactinemia no tumoral (5,8,20). Sin embargo, la mayoría de las pacientes en quienes se documentó el uso de estos medicamentos presentaron de forma concomitante prolactinoma.…”

Section: Discussionunclassified

Características clínicas y presencia de prolactinoma en mujeres con hiperprolactinemia

López-Clavijo

Gaviria-Maya

Henao-Flórez

et al. 2016

iatreia

View full text Add to dashboard Cite

Objetivos: caracterizar clínicamente a las pacientes que consultaron en InSer Pereira con diagnóstico de hiperprolactinemia, y determinar la prevalencia de prolactinomas.Metodología: descripción retrospectiva de 45 pacientes con diagnóstico de hiperprolactinemia y estudio por resonancia magnética (RM) contrastada de la silla turca entre enero del 2008 y julio del 2013. Se evaluaron las manifestaciones clínicas, la etiología, el nivel sérico de prolactina y los hallazgos imaginológicos.Resultados: las manifestaciones clínicas más frecuentes fueron: infertilidad, galactorrea y oligomenorrea. Hubo 26 casos de prolactinoma (57,8 %) y 12 de hiperprolactinemia idiopá-tica (26,6 %). De los prolactinomas, 23 fueron microadenomas (tamaño promedio: 5,1 mm; DE ± 3,2 mm). El nivel sérico promedio de prolactina fue de 74,05 ng/mL (DE ± 13,33 ng/ mL). El 78 % de las pacientes con prolactinoma tenían la prolactina sérica por debajo de 70,0 ng/mL. No hubo asociación significativa entre el nivel sérico de prolactina y la presencia de prolactinoma.Conclusión: los prolactinomas son la principal causa de hiperprolactinemia y se encuentran en su mayor parte con elevaciones ligeras de la prolactina sérica. Se recomienda hacer RM contrastada de la silla turca en pacientes con hiperprolactinemia, independientemente del nivel de prolactina.

show abstract

Section: Discussionunclassified

Características clínicas y presencia de prolactinoma en mujeres con hiperprolactinemia

López-Clavijo

Gaviria-Maya

Henao-Flórez

et al. 2016

iatreia

View full text Add to dashboard Cite

show abstract

“…Urinary C-peptide measured in 310 samples collected in the field has been used to study longitudinal and cross-sectional 311 stimulated by infant nursing demand and acts to promote the uptake of glucose and 348 fatty acids by the mammary gland and the production of milk. At the same time it 349 increases insulin resistance in maternal adipose tissue, resulting in a diversion of 350 metabolic energy to milk production (Molitch, 2004). 351…”

Section: Transitions 182 183mentioning

confidence: 99%

Endocrinology, energetics, and human life history: A synthetic model

Ellison

2017

Hormones and Behavior

View full text Add to dashboard Cite

9 10 11Human life histories are shaped by the allocation of metabolic energy to 12 competing physiological domains. A model framework of the pathways of energy 13 allocation is described and hormonal regulators of allocation along the pathways of the 14 framework are discussed in the light of evidence from field studies of the endocrinology 15 of human energetics. The framework is then used to generate simple models of two 16 important life history transitions in humans, puberty and the postpartum return to full 17 fecundity in females. The results of the models correspond very closely to observations

show abstract

Prolactinoma through the female life cycle

et al. 2017

View full text Add to dashboard Cite

Prolactinomas are the most common secretory pituitary adenoma. They typically occur in women in the 3rd-6th decade of life and rarely in the pediatric population or after menopause. Most women present with irregular menses and/or infertility. Dopamine (DA) agonists, used in their treatment, are safe during pregnancy, but in most cases are discontinued at conception with close monitoring for signs or symptoms of tumor growth. Breastfeeding is safe postpartum, provided there was no significant growth during pregnancy. Some women will experience normalization of prolactin levels postpartum. Menopause may also decrease prolactin levels and even those with macroprolactinomas may consider discontinuing their DA agonist with close follow-up. Prolactinomas may be associated with decreased quality of life scores in women, and play a role in bone health and cardiovascular risk factors. This review discusses the current literature and clinical understanding of prolactinomas throughout the entirety of the female life cycle.

show abstract

Prolactin in Human Reproduction

Cited by 6 publications

References 455 publications

Características clínicas y presencia de prolactinoma en mujeres con hiperprolactinemia

Características clínicas y presencia de prolactinoma en mujeres con hiperprolactinemia

Endocrinology, energetics, and human life history: A synthetic model

Prolactinoma through the female life cycle

Contact Info

Product

Resources

About